These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27306318)

  • 81. Significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma: a meta-analysis.
    Wu D; Jiang H; Yu H; Xu D; Liang J; Jin J
    Tumour Biol; 2013 Dec; 34(6):3865-9. PubMed ID: 23873110
    [TBL] [Abstract][Full Text] [Related]  

  • 82. XPD Asp312Asn polymorphism is a risk factor for prostate cancer.
    Liao SG; Liu L; Wang Y; Zhang YY; Wang YJ
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1689-95. PubMed ID: 22644997
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Systematic analyses and comprehensive field synopsis of genetic association studies in hepatocellular carcinoma.
    Dong D; Zou Y; Zhang P; Wu Z
    Oncotarget; 2016 Jul; 7(29):45757-45763. PubMed ID: 27304192
    [TBL] [Abstract][Full Text] [Related]  

  • 84. DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis.
    Mocellin S; Verdi D; Nitti D
    Carcinogenesis; 2009 Oct; 30(10):1735-43. PubMed ID: 19706646
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Associations between XPD Asp312Asn polymorphism and risk of head and neck cancer: a meta-analysis based on 7,122 subjects.
    Hu YY; Yuan H; Jiang GB; Chen N; Wen L; Leng WD; Zeng XT; Niu YM
    PLoS One; 2012; 7(4):e35220. PubMed ID: 22536360
    [TBL] [Abstract][Full Text] [Related]  

  • 86. New sights on the associations between the XRCC1 gene polymorphisms and hepatocellular carcinoma susceptibility.
    Cai W; Liu X; Li Y; Bi B; Liu L; Wang Z
    J Cell Biochem; 2020 Feb; 121(2):1005-1022. PubMed ID: 31478224
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Smoking and selected DNA repair gene polymorphisms in controls: systematic review and meta-analysis.
    Hodgson ME; Poole C; Olshan AF; North KE; Zeng D; Millikan RC
    Cancer Epidemiol Biomarkers Prev; 2010 Dec; 19(12):3055-86. PubMed ID: 20935063
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Association between Single Nucleotide Polymorphisms and Glioma Risk: A Systematic Literature Review.
    Tavares CB; Gomes-Braga FDCSA; Sousa EB; Brito JNPO; Melo MA; Campelo V; Neto FM; de Araújo RML; Kessler IM; Sousa Júnior LM; Filho LCC; Aguiar YQ; Lopes Costa PV; da Silva BB
    Cancer Invest; 2020 Mar; 38(3):169-183. PubMed ID: 31957502
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Case-only study of interactions between DNA repair genes (hMLH1, APEX1, MGMT, XRCC1 and XPD) and low-frequency electromagnetic fields in childhood acute leukemia.
    Yang Y; Jin X; Yan C; Tian Y; Tang J; Shen X
    Leuk Lymphoma; 2008 Dec; 49(12):2344-50. PubMed ID: 19052983
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Symposium overview: genetic polymorphisms in DNA repair and cancer risk.
    Hu JJ; Mohrenweiser HW; Bell DA; Leadon SA; Miller MS
    Toxicol Appl Pharmacol; 2002 Nov; 185(1):64-73. PubMed ID: 12460738
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The role of DNA damage and repair in liver cancer.
    Gillman R; Lopes Floro K; Wankell M; Hebbard L
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188493. PubMed ID: 33316376
    [TBL] [Abstract][Full Text] [Related]  

  • 92. GWAS reveals variants for alcohol-related hepatocellular carcinoma.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2022 Feb; 19(2):79. PubMed ID: 35017673
    [No Abstract]   [Full Text] [Related]  

  • 93. Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses.
    Chen L; Fan Z; Zhao Y; Yang H; Lv G
    J Hepatol; 2023 Jul; 79(1):e33-e35. PubMed ID: 36608772
    [No Abstract]   [Full Text] [Related]  

  • 94. Reply to: "Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses".
    Nahon P; Trépo E
    J Hepatol; 2023 Jul; 79(1):e35-e37. PubMed ID: 36822477
    [No Abstract]   [Full Text] [Related]  

  • 95. [Hepatocellular carcinoma associated genes].
    Kato N
    Nihon Shokakibyo Gakkai Zasshi; 2013 Sep; 110(9):1591-6. PubMed ID: 24005098
    [No Abstract]   [Full Text] [Related]  

  • 96. Society of Toxicology meeting. Toxicologists hit the West Coast.
    Kaiser J
    Science; 2001 May; 292(5518):837-8. PubMed ID: 11341271
    [No Abstract]   [Full Text] [Related]  

  • 97. Letter: proton pump inhibitors use and risk of hepatocellular carcinoma: A meta-analysis of observational studies.
    Zhao J; Hua L; Li N; An R; Liang C
    Aliment Pharmacol Ther; 2018 Oct; 48(8):886-888. PubMed ID: 30281834
    [No Abstract]   [Full Text] [Related]  

  • 98. Aetiology of hepatocellular carcinoma in South America.
    Ponzetto A; Diella FA; Holton J
    Liver Int; 2018 May; 38(5):956-957. PubMed ID: 29368452
    [No Abstract]   [Full Text] [Related]  

  • 99. Early hepatocellular carcinoma in South America: What is to blame?
    Debes JD
    Liver Int; 2018 May; 38(5):957-958. PubMed ID: 29702743
    [No Abstract]   [Full Text] [Related]  

  • 100. Uncommon variants of hepatocellular carcinoma: Not one size fits all.
    Kundu R; Gupta N; Chatterjee D; Duseja A
    Diagn Cytopathol; 2022 Jan; 50(1):28-31. PubMed ID: 34837485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.